past
decad
china
comput
drug
design
discoveri
research
experienc
fast
develop
variou
novel
methodolog
applic
method
span
wide
rang
drug
target
identif
hit
discoveri
lead
optim
review
firstli
provid
overview
china
statu
field
briefli
analyz
possibl
reason
rapid
advanc
methodolog
develop
outlin
select
method
short
background
preced
assess
method
respect
need
drug
discoveri
particular
work
china
highlight
furthermor
sever
success
applic
method
illustr
final
conclud
discuss
current
major
challeng
futur
direct
field
review
see
front
matter
sinc
emerg
end
comput
drug
discoveri
design
cddd
experienc
rapid
increas
develop
china
made
signific
contribut
consist
financi
support
govern
tremend
research
effort
overal
research
level
china
field
continu
advanc
trend
partial
reveal
brief
analysi
research
output
past
year
take
structurebas
drug
design
sbdd
exampl
public
scientif
paper
china
rank
fifth
citat
rank
seventh
behind
usa
uk
germani
franc
itali
among
asian
countri
china
rank
top
number
public
citat
current
univers
research
institut
china
establish
drug
design
research
depart
center
domest
research
group
engag
drug
design
main
reason
rapid
advanc
research
ascrib
major
breakthrough
methodolog
softwar
develop
current
mani
technolog
develop
boost
effici
drug
discoveri
process
research
china
follow
recent
trend
scientif
advanc
brought
us
wealth
innov
especi
develop
cddd
approach
review
first
summar
lead
comput
techniqu
tabl
includ
target
predict
drug
reposit
approach
dock
score
algorithm
virtual
screen
vs
lead
optim
techniqu
well
new
absorpt
distribut
metabol
excret
toxic
admet
relat
framework
focu
china
help
drive
new
effort
field
second
section
show
approach
success
appli
drug
discoveri
final
section
discuss
uptod
research
final
symphoni
success
case
bind
kinet
simul
paradigm
drug
target
bind
kinet
calcul
expect
inspir
futur
research
comput
strategi
techniqu
drug
design
drug
target
predict
identifi
target
first
key
step
drug
discoveri
pipelin
identifi
molecular
target
fdaapprov
drug
although
total
figur
debat
significantli
lower
number
protein
unveil
complet
human
numer
pathogen
genom
mani
potenti
druggabl
moreov
mani
drug
elicit
therapeut
activ
modul
multipl
target
multitarget
interact
either
larg
unknown
insuffici
understood
case
use
comput
tool
predict
protein
target
small
molecul
gain
import
recent
year
one
comput
approach
demonstr
effici
cost
effect
target
identif
revers
dock
molecular
dock
method
predict
predomin
bind
mode
ligand
protein
known
structur
routin
use
structurebas
drug
discoveri
hit
identif
vs
lead
optim
detail
method
provid
section
proteinligand
interact
revers
dock
opposit
convent
process
dock
applic
exampl
structurebas
vs
revers
dock
associ
larg
databas
potenti
drug
target
pdtd
userfriendli
web
sever
pharmmapp
pharmacophor
map
autogener
structur
small
molecul
userfriendli
web
sever
fast
fit
batch
process
mirtarclip
sequenc
analysi
mirna
target
predict
use
clip
sequenc
data
userfriendli
web
sever
drug
reposit
stitch
search
tool
interact
chemic
explor
known
predict
interact
chemic
protein
userfriendli
web
sever
visual
present
result
network
drug
reposit
li
et
al
largescal
dock
predict
novel
drugtarget
interact
sea
ligandbas
similar
compar
target
similar
ligand
bind
userfriendli
web
sever
structur
drug
molecul
requir
nbi
ewnbi
nwnbi
structur
pattern
favor
unfavor
herg
potassium
channel
blockag
highlight
structur
ligand
requir
herg
predict
di
martino
et
al
explain
structureact
relationship
congener
chemic
pkkb
web
servic
admet
properti
search
high
qualiti
admet
data
drug
molecul
admetsar
web
servic
admet
properti
search
userfriendli
web
server
variou
admetrel
databas
predefin
sar
model
allow
user
predict
chemic
databas
metaadedb
onlin
web
servic
ade
properti
search
userfriendli
web
server
predefin
sar
model
allow
user
predict
chemic
databas
review
trend
pharmacolog
scienc
octob
vol
dock
given
small
molecul
predefin
bind
site
pool
protein
structur
comparison
two
paradigm
shown
figur
identifi
protein
hit
serv
potenti
candid
target
experiment
valid
li
et
al
present
comput
tool
name
target
fish
dock
tarfisdock
consist
frontend
web
interfac
backend
use
dock
revers
dock
featur
work
companion
potenti
drug
target
databas
pdtd
contain
entri
potenti
drug
target
repositori
drug
target
categor
type
accord
therapeut
area
constitut
comprehens
valuabl
sourc
identifi
potenti
target
small
molecul
search
pdtd
tarfisdock
predict
potenti
bind
target
given
small
molecul
also
provid
valuabl
inform
relat
diseas
biolog
function
regul
signal
pathway
far
tarfisdock
use
evalu
small
molecul
user
countri
region
predict
result
verifi
bioassay
crystallograph
studi
despit
increas
effici
conveni
dockingbas
method
still
take
consider
amount
comput
resourc
singl
job
may
involv
execut
hundr
even
thousand
molecular
dock
run
moreov
heavili
reli
avail
structur
target
priori
knowledg
ligand
bind
site
result
method
appropri
assess
larg
batch
small
molecul
pharmacophor
model
anoth
frequent
use
techniqu
drug
hit
discoveri
usual
requir
less
time
screen
ligand
dock
measur
extent
queri
molecul
possess
spatial
arrang
featur
essenti
proteinligand
interact
similar
molecular
dock
approach
also
use
revers
screen
given
small
molecul
collect
predefin
pharmacophor
repres
differ
target
bind
site
recent
liu
et
al
report
free
web
server
host
larg
repertoir
pharmacophor
essenti
interact
mode
ligand
probe
potenti
target
entitl
pharmmapp
total
pharmacophor
construct
use
protein
structurebas
model
approach
given
queri
small
molecul
pharmmapp
automat
start
procedur
revers
map
deposit
model
output
top
rank
hit
owe
high
throughput
abil
pharmmapp
use
largescal
target
screen
profil
regul
genom
network
mirna
small
noncod
rna
molecul
capabl
suppress
protein
synthesi
regul
gene
mani
organ
abil
make
mirna
promis
technolog
futur
therapeut
develop
dysregul
mirna
function
chang
mirna
express
level
relat
mani
disord
includ
cancer
metabol
neurodegen
diseas
therefor
particular
interest
reliabl
predict
potenti
mirna
target
might
involv
diseas
mammal
mirna
associ
member
argonaut
ago
protein
famili
function
multiprotein
complex
direct
mrna
cleavag
repress
translat
complementari
rna
howev
molecular
detail
interact
mirna
target
rna
associ
ago
lack
wang
et
al
analyz
rnabound
rnafre
ago
form
perform
molecular
dock
molecular
dynam
simul
bind
free
energi
calcul
pang
et
al
investig
role
mirna
choriocarcinoma
combin
usag
silico
mirna
target
predict
luciferas
function
assay
western
blot
analysi
studi
demonstr
tumor
suppress
mirna
choriocarcinoma
cell
may
use
therapeut
target
treat
choriocarcinoma
recent
comput
approach
develop
predict
mirna
target
chou
et
al
report
systemat
approach
identifi
mirnatarget
interact
mti
mine
mirnatarget
site
crosslink
immunoprecipit
clip
photoactivat
ribonucleosideenhanc
clip
parclip
sequenc
data
name
mirtarclip
workflow
integr
webbas
browser
provid
userfriendli
interfac
detail
annot
mti
addit
find
novel
drug
target
anoth
practic
boost
product
current
drug
design
process
find
new
use
exist
drug
concept
also
known
drug
reposit
also
known
drug
repurpos
reprofil
gain
consider
attent
recent
start
point
drug
reposit
usual
approv
drug
known
bioavail
safeti
profil
approach
significantli
reduc
failur
risk
associ
drug
develop
potenti
facilit
reposit
compound
enter
clinic
phase
rapidli
less
costli
new
chemic
entiti
given
reposit
drug
current
market
discov
chanc
great
interest
develop
comput
method
ration
facilit
process
knowledg
interact
protein
small
molecul
essenti
develop
drug
reposit
tool
databas
focu
biolog
action
drug
exampl
drugbank
ttd
supertarget
matador
recent
kuhn
et
al
report
stitch
search
tool
interact
chemic
integr
inform
interact
metabol
pathway
crystal
structur
bind
experi
drugtarget
relationship
latest
version
databas
contain
chemic
million
protein
organ
basi
resourc
mani
comput
model
develop
predict
characterist
interact
exist
drug
novel
molecular
target
target
across
assess
ligandtarget
pathway
analysi
prospect
reposit
li
et
al
perform
largescal
molecular
dock
small
molecul
drug
drugbank
human
protein
drug
target
order
map
drugtarget
interact
space
find
novel
interact
method
emphas
remov
fals
posit
predict
use
annot
known
interact
consensu
score
rank
threshold
util
method
verifi
predict
novel
drugtarget
interact
literatur
search
top
rank
interact
found
correspond
experiment
evid
method
also
use
identifi
cancer
drug
nilotinib
potent
inhibitor
target
inflammatori
diseas
basi
central
premis
medicin
chemistri
structur
similar
molecul
similar
biolog
activ
potenti
drug
target
associ
small
molecul
known
pharmacolog
properti
chemic
similar
shoichet
colleagu
develop
statisticsbas
chemoinformat
method
name
sea
similar
ensembl
approach
compar
target
similar
ligand
bind
approach
use
predict
new
offtarget
purchas
fdaapprov
small
molecul
drug
pharmaceut
compound
overal
pair
drug
ligand
set
show
statist
signific
subsequ
pharmacolog
experi
confirm
new
drugtarget
associ
reveal
crossact
drug
gproteincoupl
receptor
gpcr
ion
channel
hiv
revers
transcriptas
result
suggest
polypharmacolog
wide
exist
probabl
therapeut
essenti
type
drug
besid
classic
targetand
ligandbas
comput
method
recent
year
mani
drug
reposit
approach
base
system
biolog
develop
cheng
et
al
propos
unweight
networkbas
infer
nbi
method
use
topolog
similar
ligandtarget
network
priorit
new
target
given
drug
vice
versa
new
drugtarget
interact
five
known
drug
predict
confirm
vitro
assay
one
restrict
nbi
suitabl
drug
initi
link
target
network
tackl
problem
develop
edgeweight
nbi
ewnbi
nodeweight
nbi
nwnbi
integr
nbi
similar
strategi
one
signific
advantag
propos
approach
abl
predict
protein
target
small
molecul
even
structur
protein
small
molecul
unknown
similar
abovement
drug
target
predict
approach
potenti
valu
gain
insight
promiscu
natur
drug
among
variou
comput
approach
molecular
dock
play
central
role
predict
proteinligand
interact
extens
use
drug
hit
discoveri
lead
optim
although
detail
algorithm
implement
may
differ
dock
involv
conform
sampl
compon
gener
theoret
conform
bind
pocket
review
trend
pharmacolog
scienc
octob
vol
bind
affin
relat
score
compon
rank
conform
evalu
frequent
use
dock
program
found
elsewher
gener
trend
accuraci
systemdepend
suggest
test
method
specif
particular
protein
famili
signific
progress
present
sever
research
group
china
recent
gasdock
develop
li
et
al
ultrafast
flexibl
dock
program
featur
conformationsampl
algorithm
util
entropybas
genet
algorithm
optim
bind
pose
small
molecul
increas
accuraci
speed
program
li
et
al
subsequ
develop
new
optim
model
base
improv
adapt
genet
algorithm
techniqu
includ
multipopul
genet
strategi
new
iter
scheme
adopt
model
show
reason
predict
accuraci
reproduc
nativ
bind
pose
dock
time
proport
number
rotat
bond
ligand
continu
previou
work
also
present
two
multiobject
optim
method
mosfom
solut
simultan
satisfi
energi
shape
complementar
goal
effect
enhanc
perform
compar
singl
score
gasdock
instead
accur
predict
bind
free
energi
mosfom
could
yield
reason
rank
bind
pose
elimin
conform
satisfi
overal
object
function
one
factor
influenc
reliabl
molecular
dock
protein
flexibl
increas
experiment
evid
show
mani
protein
may
undergo
signific
conform
chang
upon
ligand
bind
tradit
dock
method
assum
rigid
protein
consequ
accuraci
limit
inducedfit
proteinligand
system
howev
owe
larg
size
mani
degre
freedom
protein
comput
complex
algorithm
account
protein
flexibl
increas
dramat
sever
approxim
frequent
use
account
protein
flexibl
includ
soft
dock
side
chain
flexibl
molecular
relax
protein
ensembl
dock
koska
et
al
propos
twostag
protein
flexibl
dock
protocol
model
flexibl
protein
ligand
placement
protein
side
chain
conform
firstli
calcul
low
energi
pose
ligand
obtain
dock
comput
bind
site
hotspot
side
chain
protein
refin
energi
minim
ligand
pose
presenc
protein
perform
sherman
et
al
present
novel
procedur
model
ligandreceptor
induc
fit
effect
ligand
protein
flexibl
accur
consid
iter
combin
rigid
receptor
dock
glide
protein
structur
predict
prime
techniqu
compar
tradit
rigid
receptor
dock
approach
show
significantli
improv
success
rate
reproduc
correct
ligand
bind
pose
test
set
contain
pharmaceut
relev
exampl
although
flexibl
dock
procedur
mainli
focus
flexibl
protein
side
chain
extend
consid
backbon
motion
incorpor
loop
predict
modul
score
pose
anoth
major
obstacl
reliabl
molecular
dock
current
score
function
dock
typic
classifi
forc
fieldbas
empir
knowledgebas
forcefield
base
method
employ
classic
molecular
mechan
model
comput
direct
noncoval
interact
protein
ligand
van
der
waal
electrostat
energi
empir
score
function
contrast
decompos
overal
interact
differ
energet
term
obtain
weight
factor
regress
analys
experiment
proteinligand
bind
affin
gener
forcefield
method
wider
applic
empir
score
function
make
accur
predict
within
rang
regress
model
knowledgebas
method
knowledg
mean
structur
inform
experiment
determin
proteinligand
complex
type
method
use
boltzmann
law
transform
atom
pair
prefer
distancedepend
pairwis
potenti
result
usual
show
reason
accuraci
reproduc
experiment
bind
pose
less
accur
approxim
bind
free
energi
shen
et
al
report
improv
knowledgebas
score
function
name
ipmf
typic
knowledgebas
function
develop
appli
boltzmann
law
transform
atom
pair
prefer
distancedepend
pairwis
potenti
addit
structur
inform
ipmf
integr
experiment
bind
affin
inform
extract
potenti
via
iter
optim
approach
found
score
function
enrich
knowledg
might
achiev
increas
accuraci
bind
affin
predict
compar
seven
commonli
use
score
function
third
parti
test
set
contain
divers
proteinligand
complex
ipmf
perform
best
predict
bind
affin
rapid
grow
volum
highqual
structur
proteinligand
interact
data
public
domain
work
repres
posit
step
toward
improv
accuraci
score
bind
affin
predict
perspect
comput
drug
design
drug
discoveri
process
commonli
involv
two
step
hit
identif
lead
optim
hit
identif
relat
method
frequent
investig
search
compound
interest
biolog
activ
also
known
vs
pharmacophorebas
vs
establish
silico
tool
result
identif
mani
activ
compound
drug
discoveri
program
gener
pharmacophor
model
deduc
set
ligand
known
activ
structur
receptor
lack
sever
program
automat
ligandbas
pharmacophor
deriv
develop
show
differ
abil
retriev
activ
compound
altern
pharmacophor
model
directli
gener
protein
crystal
structur
reveal
key
element
requir
proteinligand
bind
fast
advanc
structur
biolog
develop
reliabl
protein
structurebas
pharmacophor
gain
attent
chen
lai
develop
tool
review
trend
pharmacolog
scienc
octob
vol
name
pocket
gener
pharmacophor
model
base
given
receptor
complex
structur
approach
hotspot
analysi
gridbas
score
use
identifi
essenti
pharmacophor
featur
suggest
case
studi
result
pocket
yield
consist
pharmacophor
model
protein
minor
conform
chang
upon
bind
differ
ligand
indic
robust
approach
shapebas
vs
anoth
use
tool
search
novel
lead
compound
follow
frequent
use
similar
concept
assum
molecul
shape
chemistri
compar
known
activ
agent
signific
probabl
show
similar
biolog
activ
definit
shape
similar
usual
deriv
align
achiev
optim
overlap
structur
compound
metric
distanc
mismatch
volum
mani
applic
studi
reveal
shapebas
vs
result
good
enrich
activ
compound
meanwhil
suffici
divers
discov
compound
suggest
compar
studi
hawkin
et
al
shape
match
show
better
vs
perform
molecular
dock
test
case
liu
et
al
report
use
vs
tool
name
shaft
shape
featur
similar
hybrid
approach
molecular
similar
search
compar
molecular
shape
pharmacophor
featur
shaft
perform
rigid
bodi
superimposit
molecular
model
use
singl
multipl
bioactiv
compound
queri
templat
basi
featur
triplet
hash
algorithm
shaft
effici
perform
rigid
bodi
superimposit
molecular
model
queri
bioactiv
compound
compar
ligandbas
vs
method
also
achiev
superior
perform
enrich
assess
measur
number
activ
compound
found
employ
certain
vs
strategi
oppos
number
found
random
sampl
result
suggest
shaft
suitabl
largescal
vs
prospect
explor
potenti
mechan
drug
side
effect
commerci
chemic
librari
highthroughput
screen
ht
primari
sourc
hit
identif
although
increas
size
avail
librari
rais
possibl
find
use
compound
great
interest
design
new
compound
independ
known
chemic
structur
use
de
novo
method
yuan
et
al
propos
de
novo
structurebas
drug
design
program
ligbuild
automat
build
screen
ligand
molecul
within
bind
pocket
target
protein
updat
version
program
synthesi
access
design
compound
analyz
aid
embed
chemic
reaction
databas
retrosynthesi
analyz
recurs
check
target
molecul
precursor
structur
obtain
retrosynthet
rule
found
databas
ligbuild
use
pocket
defin
pharmacophor
featur
within
bind
pocket
quantit
calcul
ligand
bind
site
provid
visual
present
properti
site
also
allow
user
pick
remov
fragment
lead
use
grow
link
strategi
optim
way
also
serv
effect
tool
fragmentbas
lead
optim
one
critic
challeng
de
novo
drug
design
select
fragment
set
best
potenti
part
new
drug
lead
given
target
virtual
librari
construct
suggest
one
potenti
solut
chen
et
al
establish
approach
build
targetfocus
librari
find
hit
toward
studi
target
combin
score
structur
divers
bind
affin
druglik
assess
test
construct
peroxisom
proliferatoractiv
receptor
g
pparg
focus
librari
model
success
reproduc
key
substructur
fdaapprov
drug
also
gener
novel
chemic
class
increas
vitro
inhibit
activ
pparg
respect
time
softwar
packag
name
develop
new
approach
activ
hit
obtain
ht
typic
exhibit
low
medium
level
activ
subsequ
modifi
improv
potenc
select
incorpor
favor
physic
chemic
properti
recent
li
et
al
devis
method
call
autot
automat
tailor
transplant
captur
strong
bind
fragment
hit
vs
output
transplant
lead
compound
novel
optim
chemic
structur
mean
approach
need
perform
sampl
possibl
combin
fragment
conform
result
molecul
structur
oper
make
effici
convent
de
novo
design
method
anoth
appar
advantag
autot
reli
predefin
librari
build
block
detect
import
fragment
vs
hit
featur
expand
applic
vs
hit
discoveri
lead
optim
tradit
chines
medicin
tcm
quintess
chines
cultur
heritag
constitut
valuabl
sourc
hit
identif
lead
optim
increas
effort
devot
studi
tcm
result
larg
number
isol
bioactiv
compound
recent
chen
construct
structur
tcm
databas
databas
taiwan
base
structur
collect
chines
medic
literatur
scientif
public
furthermor
base
databas
tsai
et
al
construct
web
comput
system
tcm
intellig
screen
system
iscreen
provid
user
access
tcm
databas
perform
vs
de
novo
drug
design
onlin
silico
predict
admet
properti
studi
admet
commenc
highlight
contribut
properti
failur
rate
drug
discoveri
result
mount
cost
bring
new
drug
market
meanwhil
number
market
drug
withdraw
continu
increas
mainli
underli
admet
issu
could
detect
earlier
current
mani
solut
propos
identifi
address
issu
lead
compound
progress
clinic
stage
among
role
earli
screen
admet
properti
silico
tool
wide
appreci
metabol
biotransform
new
chemic
entiti
high
interest
may
profoundli
affect
bioavail
activ
toxic
profil
cytochrom
trend
pharmacolog
scienc
octob
vol
cyp
major
enzym
involv
process
respons
metabol
fdaapprov
drug
zheng
et
al
report
site
metabol
som
predict
six
import
metabol
reaction
incorpor
use
machin
learn
semiempir
quantum
chemic
calcul
intern
extern
valid
result
suggest
develop
model
reason
success
furthermor
shen
et
al
develop
webbas
som
predict
servic
someviz
provid
medicin
chemist
visual
easytous
interfac
address
metabolismrel
problem
although
consider
overlap
present
individu
isoenzym
uniqu
substrat
specif
recent
zaretzki
et
al
develop
server
name
rswebpredictor
predict
isozymespecif
regioselect
reaction
given
genet
polymorph
enzym
valuabl
inform
may
provid
basi
understand
predict
individu
differ
drug
respons
blockad
human
etheragogo
relat
gene
herg
potassium
channel
identifi
import
mechan
qt
interv
prolong
lead
sever
cardiotox
result
withdraw
mani
major
drug
therefor
import
assess
herg
bind
compound
earli
phase
drug
discoveri
basi
divers
set
compound
wang
et
al
develop
ligandbas
classif
model
herg
blockad
predict
model
achiev
accuraci
one
intern
two
extern
test
set
moreov
import
structur
fragment
favor
unfavor
herg
channel
inhibit
highlight
accur
predict
herg
inhibitori
potenc
offer
possibl
screen
optim
hit
compound
elimin
potenti
lethal
side
effect
although
full
crystal
structur
herg
yet
avail
consider
effort
devot
develop
structurebas
model
herg
blocker
recent
di
martino
et
al
develop
valid
autom
dock
protocol
quantit
character
bind
seri
herg
channel
blocker
approach
turn
success
increas
consist
dock
bind
mode
explain
structureact
relationship
blocker
clearli
structur
major
admetrel
protein
becom
avail
structurebas
model
play
increasingli
import
role
field
hou
colleagu
carri
extens
studi
silico
model
variou
admetrel
properti
includ
bloodbrain
barrier
partit
permeabl
human
intestin
absorpt
hia
oral
absorpt
oral
bioavail
pglycoprotein
inhibit
etc
recent
contribut
develop
combin
databas
pkkb
pharmacokinet
knowledg
base
collect
structur
pharmacolog
inform
import
experiment
predict
physiochem
properti
experiment
admet
data
drug
databas
provid
use
resourc
benchmark
pharmacokinet
studi
valid
accuraci
exist
admet
predict
model
build
new
predict
model
web
servic
admetsar
http
wwwadmetexporg
develop
cheng
et
al
comprehens
sourc
chemic
admet
properti
provid
userfriendli
interfac
databas
cover
admet
annot
data
point
uniqu
compound
type
admetassoci
properti
moreov
databas
includ
classif
regress
model
highli
predict
accuraci
allow
user
predict
properti
chemic
found
databas
recent
cheng
et
al
report
databas
advers
drug
event
ade
name
metaadedb
collect
data
integr
text
mine
databas
includ
drugad
associ
among
compound
ade
item
addit
comput
modul
develop
predict
potenti
ade
base
databas
phenotyp
network
infer
model
pnim
show
high
predict
accuraci
extern
valid
set
extract
usfda
advers
event
report
system
success
applic
comput
drug
discoveri
design
outlin
novel
comput
tool
strategi
recent
report
china
cover
aspect
drug
discoveri
develop
process
overal
profound
impact
ration
drug
design
approach
may
potenti
significantli
acceler
streamlin
stage
drug
discoveri
conjunct
techniqu
follow
section
demonstr
method
success
appli
differ
drug
discoveri
phase
case
drug
target
identif
natur
product
provid
vast
sourc
discoveri
use
therapeut
molecular
target
mani
natur
product
remain
unknown
unravel
target
target
natur
compound
provid
insight
molecular
mechan
help
optim
potenc
select
pathogen
bacterium
helicobact
pylori
major
caus
factor
gastrointestin
ill
natur
product
isol
ceratostigma
willmottianum
folk
medicin
use
remedi
rheumat
traumat
injuri
parot
found
effect
inhibit
bacterium
howev
specif
mechan
action
compound
unknown
cai
et
al
use
compound
probe
search
pdtd
tarfisdock
total
put
interact
protein
found
among
diaminopimel
decarboxylas
dc
peptid
deformylas
pdf
show
share
sequenc
homolog
h
pylori
particularli
sequenc
h
pylori
pdf
hppdf
share
ident
escherichia
coli
pdf
interact
natur
product
two
protein
experiment
evalu
enzymat
assay
demonstr
natur
product
one
analog
potent
inhibitor
hppdf
ic
valu
mm
respect
moreov
later
determin
xray
crystal
structur
apohppdf
inhibitorhppdf
complex
confirm
atom
level
studi
reveal
hppdf
potenti
target
antih
trend
pharmacolog
scienc
octob
vol
pylori
agent
anoth
interest
find
use
tarfisdock
includ
reveal
mechan
gingerol
activ
constitu
fresh
ginger
cancer
control
manag
exhibit
consider
physiolog
effect
antioxid
antiinflammatori
antitumorigen
activ
exact
molecular
mechan
action
remain
elus
tarfisdock
jeong
et
al
ascertain
gingerol
suppress
carcinogenesi
inhibit
enzymat
activ
leukotrien
hydrolas
lta
h
given
leukotrien
lta
h
overexpress
sever
human
cancer
cell
line
includ
colorect
cancer
find
support
anticanc
efficaci
gingerol
torcetrapib
cholesteryl
ester
transfer
protein
cetp
inhibitor
suppress
exchang
lower
high
densiti
lipoprotein
hdl
triglyceriderich
lipoprotein
patient
hyperlipidemia
also
document
may
induc
cardiac
event
associ
sever
advers
effect
howev
detail
mechan
regard
safeti
issu
torcetrapib
still
lack
fan
et
al
establish
system
biolog
approach
combin
human
reassembl
signal
network
microarray
gene
express
data
studi
drugtarget
interact
torcetrapib
furthermor
obtain
potenti
offtarget
torcetrapib
identifi
employ
revers
dock
strategi
result
suggest
plateletderiv
growth
factor
receptor
pdgfr
hepatocyt
growth
factor
receptor
hgfr
receptor
epiderm
growth
factor
receptor
tyrosin
kinas
highli
relev
unfavor
advers
effect
anoth
case
studi
silico
target
predict
includ
fibroblast
growth
factor
receptor
fgfr
famili
four
structurerel
receptor
tyrosin
kinas
target
treatment
variou
human
cancer
qian
colleagu
use
revers
pharmacophor
map
approach
pharmmapp
identifi
target
candid
activ
compound
previous
synthes
show
great
vitro
antiprolif
effect
among
predict
target
candid
tyrosin
kinas
reveal
potenti
target
compound
result
subsequ
valid
enzymelink
immunosorb
assay
follow
structur
optim
deriv
compound
found
effect
antiprolif
inhibitor
cancer
cell
line
micromolar
submicromolar
ic
valu
hit
discoveri
molecular
dock
one
wide
employ
techniqu
normal
embed
workflow
differ
silico
well
experiment
approach
liu
et
al
report
combinatori
comput
strategi
discov
potenti
inhibitor
insulinlik
growth
receptor
belong
tyrosin
kinas
famili
play
pivot
role
signal
pathway
involv
cell
growth
prolifer
apoptosi
initi
hit
obtain
hierarch
vs
subsequ
use
queri
scaffold
substructur
search
build
focus
librari
librari
screen
inhous
pharmacophoreconstrain
dock
protocol
pacdock
eventu
purchas
compound
exhibit
inhibitori
activ
enzymat
assess
strikingli
two
potent
inhibitor
demonstr
excel
inhibitori
potenc
ic
nm
respect
also
present
consider
select
insulin
receptor
ir
highli
homolog
asid
potenti
antitumor
agent
promis
select
inhibitor
investig
molecular
probe
differenti
biolog
function
ir
new
delhi
recent
attract
extens
attent
rapid
dissemin
resist
almost
known
blactam
antibiot
use
twostag
protein
flexibl
dock
protocol
mention
methodolog
section
shen
et
al
establish
interact
model
thiophenecarboxyl
acid
inhibitor
result
reveal
sulfur
atom
ligand
might
interfer
water
bridg
zinc
ion
activ
site
provid
use
clue
ration
design
effect
inhibitor
anoth
distinguish
contribut
made
chines
research
identif
new
indic
old
drug
cinanserin
wellcharacter
serotonin
antagonist
sever
acut
respiratori
syndrom
sar
outbreak
china
spring
dockingbas
vs
chen
et
al
identifi
cinanserin
potenti
inhibitor
proteas
sar
later
experiment
test
show
cinanserin
inde
inhibit
proteas
ic
mm
nontox
drug
concentr
potenti
kill
sar
viru
old
drug
cheap
establish
safeti
record
cinanserin
could
use
emerg
treatment
stockpil
futur
sar
pandem
paradigm
repurpos
exist
drug
provid
costeffect
new
way
tackl
devast
diseas
ligandbas
vs
integr
tool
chest
comput
chemist
effect
dock
vs
highli
variabl
owe
mani
factor
protein
flexibl
score
problem
liu
et
al
report
appli
shaft
discoveri
novel
inhibitor
ribosom
protein
kinas
play
pivot
role
regul
divers
cellular
process
shaft
use
perform
similar
search
adopt
two
weak
inhibitor
queri
templat
sixteen
compound
discov
ic
mm
three
show
low
micromolar
inhibitori
activ
exhibit
select
across
panel
relat
kinas
contrast
new
scaffold
identifi
convent
fingerprint
method
result
suggest
shaft
effici
power
tool
scaffoldhop
hit
identif
endeavor
custom
design
librari
focus
target
interest
expect
select
assembl
fragment
set
best
potenti
part
new
drug
lead
target
help
technolog
use
design
focus
librari
lead
structur
trend
pharmacolog
scienc
octob
vol
optim
well
document
illustr
combin
lead
optim
strategi
three
case
studi
highlight
issu
success
observ
screen
targetfocus
librari
first
success
applic
discoveri
three
seri
potent
inhibitor
bhydroxyacylacyl
carrier
protein
dehydratas
fabz
h
pylori
hpfabz
intens
interest
treatment
gastric
diseas
basi
fragment
isol
previous
discov
hpfabz
inhibitor
focus
librari
design
program
dock
bind
pocket
candid
synthes
test
bioassay
among
eight
compound
show
signific
inhibitori
activ
ic
valu
rang
mm
high
hit
rate
demonstr
effici
focus
librari
moreov
adopt
similar
strategi
liu
et
al
report
novel
purin
deriv
potent
select
inhibitori
activ
csrc
kinas
remark
agent
show
kinas
inhibitori
activ
ic
valu
mm
make
potenti
lead
develop
csrc
kinaserel
anticanc
drug
last
excel
work
present
design
inhibitor
cyclophilin
cypa
respons
varieti
biolog
process
regul
via
peptidylprolyl
isomeras
ppias
activ
also
report
promis
target
cardiovascular
immunosuppress
cancer
therapi
initi
li
et
al
design
focus
librari
basi
previous
report
cypa
inhibitor
select
compound
synthesi
compound
cypa
binder
dissoci
constant
k
rang
mm
five
compound
show
ppias
inhibitori
activ
ic
mm
hit
rate
binder
inhibitor
high
respect
encourag
result
author
continu
studi
acylurea
linker
previous
identifi
crucial
cypa
ligand
bind
de
novo
drug
design
program
ligbuild
custom
gener
inhibitor
incorpor
complementari
properti
fit
shape
cypa
bind
site
potent
inhibitor
ic
nm
firstli
obtain
two
round
structureact
analys
sar
chemic
modif
two
highli
potent
cypa
inhibitor
nanomolar
inhibitori
potenc
nm
nm
obtain
synthes
compound
promis
result
clearli
demonstr
de
novo
method
ligbuild
power
tool
lead
optim
year
mark
three
decad
protein
structurebas
drug
design
sinc
first
dock
program
dock
publish
kuntz
et
al
special
issu
publish
journal
computeraid
molecular
design
reflect
year
molecular
design
conclud
new
compound
easi
design
challeng
evalu
medicin
chemist
use
varieti
comput
approach
modifi
chemic
structur
compound
maxim
vitro
activ
howev
good
vitro
activ
extrapol
good
vivo
activ
without
understand
pharmacokinet
drug
metabol
properti
even
proteinligand
bind
level
challeng
predict
efficaci
ligand
tradit
drug
discoveri
driven
idea
ligand
higher
bind
affin
target
efficaci
lower
bind
affin
target
clear
efficaci
drug
associ
thermodynam
also
relat
bind
kinet
drug
defin
target
numer
exampl
demonstr
drug
efficaci
alway
linearli
correl
bind
affin
particular
renew
emphasi
ligandreceptor
bind
kinet
almost
step
along
drug
research
develop
r
pipelin
similar
experiment
approach
drug
discoveri
current
comput
drug
design
method
focu
maxim
ligandbind
affin
either
fastbutinaccur
slowbutaccur
situat
tend
chang
develop
bind
kineticsemphas
paradigm
drug
efficaci
mainli
depend
drugtarget
resid
time
calcul
k
dissoci
rate
constant
k
despit
year
effort
predict
bind
free
energi
ligand
interact
target
suffici
accuraci
within
ae
kcalmol
still
unsolv
problem
due
timeconsum
free
energi
perturb
calcul
crude
dock
result
mention
calcul
k
recent
research
team
made
signific
progress
area
energi
landscap
theori
develop
understand
protein
fold
function
extend
develop
gener
applic
comput
framework
make
possibl
construct
complet
ligandtarget
bind
free
energi
landscap
bfel
enabl
bind
affin
bind
kinet
accur
estim
possibl
bind
unbind
pathway
may
obtain
well
appli
method
simul
bind
event
antialzheim
diseas
drug
huperzin
hupa
target
acetylcholinesteras
ach
comput
result
excel
agreement
concurr
experiment
measur
predict
valu
bind
free
energi
activ
free
energi
associ
dissoci
deviat
experiment
data
less
kcalmol
method
also
provid
atom
resolut
inform
hupa
bind
pathway
may
use
design
ach
inhibitor
higher
potenc
conclud
remark
cddd
multidisciplinari
technolog
exploit
stateofart
silico
model
algorithm
speed
drug
develop
process
past
decad
signific
progress
china
develop
applic
novel
methodolog
method
streamlin
mani
aspect
drug
discoveri
hit
screen
lead
optim
drug
target
identif
admet
assess
futur
develop
necessari
establish
research
pattern
orient
comput
analys
bring
full
play
chemistri
biolog
disciplin
review
trend
pharmacolog
scienc
octob
vol
complementari
strength
particular
philosophi
embodi
cddd
shift
one
gene
one
drug
one
diseas
multicompon
therapeut
network
target
accordingli
emerg
disciplin
network
pharmacolog
combin
network
biolog
chemogenom
make
notabl
impact
fundament
challeng
tradit
medicin
complex
diseas
new
paradigm
cddd
play
even
pivot
role
discov
lead
compound
desir
polypharmacolog
profil
systemat
data
mine
elucid
synergist
effect
side
effect
understand
promiscu
drug
